Boston Scientific Stock Set to Gain From Completion of Axonics Deal

Boston Scientific Corporation (BSX) recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The deal, originally announced in January this year, enables Boston Scientific’s entry into sacral neuromodulation (SNM), a high-growth adjacency for its Urology business.The company paid $71 cash per share to Axonics, representing an equity value of $3.7 billion and an enterprise ...